| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
|
Lancet Oncol
|
2015
|
1.45
|
|
2
|
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
|
Mod Pathol
|
2013
|
1.21
|
|
3
|
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
|
Leuk Res
|
2014
|
0.93
|
|
4
|
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
|
Mod Pathol
|
2015
|
0.92
|
|
5
|
Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
|
Blood Rev
|
2015
|
0.89
|
|
6
|
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
|
Oncotarget
|
2015
|
0.84
|
|
7
|
B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease.
|
Mod Pathol
|
2013
|
0.83
|
|
8
|
Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.
|
Mod Pathol
|
2013
|
0.83
|
|
9
|
Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes.
|
Mod Pathol
|
2014
|
0.82
|
|
10
|
Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
|
Mod Pathol
|
2015
|
0.82
|
|
11
|
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
|
Oncotarget
|
2015
|
0.82
|
|
12
|
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
|
Mod Pathol
|
2015
|
0.81
|
|
13
|
Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.
|
Mod Pathol
|
2015
|
0.81
|
|
14
|
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response.
|
Eur J Haematol
|
2015
|
0.80
|
|
15
|
B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
|
Mod Pathol
|
2014
|
0.80
|
|
16
|
Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease.
|
Mod Pathol
|
2013
|
0.80
|
|
17
|
Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.
|
Eur J Haematol
|
2015
|
0.79
|
|
18
|
Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.
|
Mod Pathol
|
2015
|
0.79
|
|
19
|
The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia.
|
Mod Pathol
|
2016
|
0.78
|
|
20
|
MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
|
Histopathology
|
2015
|
0.78
|
|
21
|
Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies.
|
Mod Pathol
|
2015
|
0.78
|
|
22
|
Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma.
|
Oncotarget
|
2016
|
0.77
|
|
23
|
Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
|
Cancer Genet
|
2016
|
0.77
|
|
24
|
Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma.
|
Ann Diagn Pathol
|
2014
|
0.76
|
|
25
|
Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
|
Histopathology
|
2015
|
0.76
|
|
26
|
Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
|
Oncotarget
|
2016
|
0.76
|
|
27
|
Crystal-storing histiocytosis: a clinicopathological study of 13 cases.
|
Histopathology
|
2015
|
0.76
|
|
28
|
Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.
|
Mod Pathol
|
2016
|
0.75
|
|
29
|
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.
|
Oncotarget
|
2017
|
0.75
|
|
30
|
Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
|
Mod Pathol
|
2017
|
0.75
|
|
31
|
Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
|
Oncotarget
|
2016
|
0.75
|
|
32
|
Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype.
|
Eur J Haematol
|
2017
|
0.75
|
|
33
|
NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.
|
Mod Pathol
|
2017
|
0.75
|
|
34
|
Characteristics and Clinical Implications of Reactive Germinal Centers in the Bone Marrow.
|
Hum Pathol
|
2017
|
0.75
|
|
35
|
Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma.
|
Mod Pathol
|
2021
|
0.75
|
|
36
|
Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.
|
Mod Pathol
|
2017
|
0.75
|
|
37
|
T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid.
|
Leukemia
|
2020
|
0.75
|
|
38
|
Phenytoin-associated necrotising lymphadenitis mimicking Kikuchi disease.
|
Pathology
|
2019
|
0.75
|
|
39
|
Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.
|
Mod Pathol
|
2017
|
0.75
|
|
40
|
Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma.
|
Br J Haematol
|
2017
|
0.75
|
|
41
|
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
|
Br J Haematol
|
2016
|
0.75
|
|
42
|
3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.
|
Mod Pathol
|
2017
|
0.75
|
|
43
|
Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.
|
Blood Rev
|
2017
|
0.75
|
|
44
|
Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.
|
Ann Diagn Pathol
|
2016
|
0.75
|
|
45
|
CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.
|
Mod Pathol
|
2017
|
0.75
|
|
46
|
Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.
|
Mod Pathol
|
2017
|
0.75
|
|
47
|
Myeloproliferative Neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: A Meta-Analysis of 20 Cases Shows Cytogenetic Progression with B-Lymphoid Blast Phase.
|
Hum Pathol
|
2017
|
0.75
|
|
48
|
Genetic alterations and their clinical implications in DLBCL.
|
Nat Rev Clin Oncol
|
2019
|
0.75
|
|
49
|
Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.
|
Mod Pathol
|
2017
|
0.75
|
|
50
|
Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up.
|
Mod Pathol
|
2021
|
0.75
|
|
51
|
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.
|
Br J Haematol
|
2015
|
0.75
|
|
52
|
Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.
|
Mod Pathol
|
2017
|
0.75
|
|
53
|
Peripheral T-cell lymphoma with unusual clinical presentation of rhabdomyolysis.
|
Hematol Oncol
|
2015
|
0.75
|
|
54
|
Hydroa vacciniforme and hydroa vacciniforme-like T-cell lymphoma: an uncommon event for transformation.
|
J Cutan Pathol
|
2016
|
0.75
|
|
55
|
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
|
Br J Haematol
|
2016
|
0.75
|